In patients with COVID-19 receiving IMV or ECMO, adding baricitinib to usual care reduced all-cause mortality

Area of Science:

• Critical care medicine
• Infectious diseases
• Pharmacology

Background:

• Severe COVID-19 patients on mechanical ventilation or ECMO have high mortality.
• Baricitinib, a Janus kinase inhibitor, has shown anti-inflammatory effects.
• Its efficacy in the most critically ill COVID-19 patients requires further investigation.

Purpose of the Study:

• To evaluate the efficacy and safety of baricitinib plus standard of care (SOC) versus placebo plus SOC.
• To assess the impact on clinical outcomes in critically ill adults with COVID-19 requiring invasive mechanical ventilation or ECMO.

Main Methods:

• Exploratory, randomized, placebo-controlled trial.
• Inclusion of critically ill hospitalized adults with COVID-19 on invasive mechanical ventilation or ECMO.
• Primary endpoint was all-cause mortality at 60 days.

Main Results:

• No significant difference in 60-day mortality between baricitinib and placebo groups (30.1% vs 27.3%, hazard ratio 1.12, 95% CI 0.85-1.47).
• No significant differences in other key clinical outcomes, including time to liberation from mechanical ventilation or ECMO.
• Adverse events were similar between groups, with a slightly higher rate of serious infections in the baricitinib arm.

Conclusions:

• Baricitinib plus SOC did not improve survival in critically ill COVID-19 patients on mechanical ventilation or ECMO.
• The drug was generally safe in this population, but did not demonstrate added clinical benefit.
• Further research may explore baricitinib in different patient subgroups or earlier disease stages.